South Africa

Bavarian monkeypox vaccine wins EU approval – SABC News

The Danish biotech company Bavarian Nordic said on Monday that the European Commission has given permission to market the vaccine Imvanex as a protection against monkeypox, in accordance with the recommendation of the European Medicines Agency (EMA) last week.

The approval comes just a day after the World Health Organization issued a high-level alert declaring the rapidly spreading monkeypox outbreak a global health emergency.

“The availability of an approved vaccine can significantly improve nations’ preparedness to combat emerging diseases, but only through investment and structured planning for biological preparedness,” said Bavarian CEO Paul Chaplin.

The Bavarian vaccine, which is the only vaccine approved in the United States and Canada to prevent monkeypox, has so far only been approved in the EU for the treatment of smallpox.
However, during the current monkeypox epidemic, the company delivered the vaccine to several EU countries for so-called “off-label” use.
The approval is valid in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway, according to a statement from Bavarian Nordic.

The development of Imvanex was made possible by significant investments by the United States government over the past two decades, the company added.

Bavarian’s shares have risen 122% in the past three months, buoyed by strong demand for the monkeypox vaccine.

Bavarian monkeypox vaccine wins EU approval – SABC News

Source link Bavarian monkeypox vaccine wins EU approval – SABC News

Back to top button